Last reviewed · How we verify
Elranatamab + lenalidomide + dexamethasone (elranatamab-lenalidomide-dexamethasone)
At a glance
| Generic name | elranatamab-lenalidomide-dexamethasone |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Bispecific antibody |
| Phase | Phase 2 |
Approved indications
Common side effects
- Anaemia
- Neutropenia
- Thrombocytopenia
- Nausea
- Vomiting
- Aspartate aminotransferase increased
- Hypomagnesaemia
- Leukopenia
- Lymphopenia
- Sinus tachycardia
- Constipation
- Diarrhoea
Key clinical trials
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (PHASE3)
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) (PHASE3)
- A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy (PHASE3)
- MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma (PHASE2)
- Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies (PHASE1, PHASE2)
- ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma (PHASE2)
- ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (PHASE2)
- Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Elranatamab + lenalidomide + dexamethasone CI brief — competitive landscape report
- Elranatamab + lenalidomide + dexamethasone updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI